Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Clinical trial NCT04111705 · COMPLETED
Trial details
- NCT number
- NCT04111705
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-05
- Primary completion
- 2022-08-11
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.